{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:37:45Z","timestamp":1790804265307,"version":"4.1.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0195325","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T14:21:50Z","timestamp":1522765310000},"page":"e0195325","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":66,"title":["Identification of HLA-DRB1 association to adalimumab immunogenicity"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-7397","authenticated-orcid":true,"given":"Mohan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Degner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Wade","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Idler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nael M.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F.","family":"Waring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.08.047","article-title":"Pathogenesis and pharmacotherapy of Hidradenitis suppurativa","author":"M Nazary","year":"2011","journal-title":"European Journal of Pharmacology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: A rationale for targeting TNF- \u03b1 and IL-1\u03b2","volume":"164","author":"HH Van Der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"AB Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"ref4","first-page":"210","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: Lessons for clinical practice","author":"T Schaeverbeke","year":"2015","journal-title":"Rheumatology (United Kingdom)"},{"key":"ref5","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","author":"S Garces","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis","volume":"29","author":"SS Thomas","year":"2015","journal-title":"BioDrugs"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"TRDJ Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"GM Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/ard.2005.049858","article-title":"High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment","volume":"65","author":"GM Bartelds","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clim.2013.09.006","article-title":"T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation","author":"V Jawa","year":"2013","journal-title":"Clinical Immunology"},{"key":"ref11","article-title":"Association of <italic>HLA-DRB1<\/italic> alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis","author":"GR Burmester","year":"2015","journal-title":"Rheumatology"},{"key":"ref12","first-page":"1037","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","author":"G-R Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.151009","article-title":"Methotrexate dosage reduction upon adalimumab initiation: Clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial","volume":"43","author":"GS Kaeley","year":"2016","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/tan.12304","article-title":"Identification of 2127 new HLA class I alleles in potential stem cell donors from Germany, the United States and Poland","volume":"83","author":"CJ Hern\u00e1ndez-Frederick","year":"2014","journal-title":"Tissue Antigens"},{"key":"ref15","article-title":"Biostatistics","volume":"38","author":"SD Walter","year":"1987"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1002\/sim.5899","article-title":"Confidence intervals after multiple imputation: Combining profile likelihood information from logistic regressions","volume":"32","author":"G Heinze","year":"2013","journal-title":"Stat Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ajhg.2008.07.006","article-title":"HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis","volume":"83","author":"S Hoffmann","year":"2008","journal-title":"Am J Hum Genet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/archneurol.2011.65","article-title":"Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis","volume":"68","author":"D Buck","year":"2011","journal-title":"Arch Neurol"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090479","article-title":"Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis","volume":"9","author":"J Link","year":"2014","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor??-expressing cells: Comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"H Mitoma","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","article-title":"Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor \u03b1-associated diseases from a molecular view","volume":"288","author":"S Hu","year":"2013","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/gutjnl-2015-309698","article-title":"Immunogenicity to infliximab is associated with HLA-DRB1","author":"T Billiet","year":"2015","journal-title":"Gut"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ando.2007.06.015","article-title":"Hormonal replacement therapy (HRT) in postmenopause: a reappraisal","volume":"68","author":"A Caufriez","year":"2007","journal-title":"Ann Endocrinol (Paris)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/gene.2014.6","article-title":"MHC associations with clinical and autoantibody manifestations in European SLE","volume":"15","author":"D Morris","year":"2014","journal-title":"Genes Immun"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0195325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T12:02:25Z","timestamp":1540036945000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0195325"}},"subtitle":[],"editor":[{"given":"Valli","family":"De Re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0195325","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]}}}